Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 66
Filter
1.
Transplant Proc ; 50(10): 3255-3257, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30577194

ABSTRACT

INTRODUCTION: Recently, more and more generic drugs have been used for immunosuppressive drugs in the field of organ transplantation. Some reports have indicated that blood concentration of most generic drugs is difficult to maintain stability, and it may cause the difference in graft survival of transplanted organs between original drugs and generic drugs. In this article, we report the cases could not maintain blood concentration of generic drugs of mycophenolate mofetil (MMF). RESULTS: In 4 cases out of 5 cases that we had to change original MMF to generic MMF, there were cases that blood concentration level was not stabilized. There were possibility that the lowered blood concentration level of MMF caused a rejection, in two cases. Mean MMF trough level was decreased from 3.6 ± 1.9 µg/mL to 0.6 ± 0.4 µg/mL. Due to the early detection, it did not become severe or failure of graft function, however, we cannot deny the possibilities that side effects were increased and rejection rose. In these cases, we discontinued to use the generic drugs thereafter due to unstable plasma concentration of MMF. DISCUSSION: Some reports have indicated that failure to maintain plasma concentration of MMF leads to rejection. Therefore, maintenance of effective plasma concentration and prevention of rejection are essential to long-term graft survival in kidney transplant. CONCLUSION: Generic drug formulations may exhibit differences in effects and absorption compared to the brand-name drug. If the generic drug should be used, patients should be closely monitored.


Subject(s)
Drug Substitution/adverse effects , Drugs, Generic/adverse effects , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/blood , Kidney Transplantation , Mycophenolic Acid/adverse effects , Adult , Child , Drug-Related Side Effects and Adverse Reactions , Female , Graft Rejection/prevention & control , Graft Survival , Humans , Japan , Male , Middle Aged , Mycophenolic Acid/blood
2.
Transplant Proc ; 50(8): 2569-2571, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30316400

ABSTRACT

Much controversy exists over the performance of elderly living donor kidney transplantation. We report the safety of 2 cases of elderly living kidney donations in our hospital. CASE 1: An 82-year-old man was a living kidney donor for his 56-year-old son. The donor suffered from hypertension, but has successfully managed his blood pressure with only one medication. His serum creatinine was 0.7 mg/dL and inulin clearance was 122.5 mL/min, which met the usual criteria for living kidney donors. This was his son's secondary kidney transplantation, and no other donors existed. CASE 2: An 80-year-old woman was a living kidney donor for her 45-year-old son. Her serum creatinine was 0.61 mg/dL and inulin clearance was 71.7 mL/min, which met the marginal kidney donor criteria. In both cases, we determined that the donor kidney function was acceptable. Though we explained the risks of the transplantation thoroughly, the patients' strong will to offer a kidney to their family member did not change. We decided to carry out the transplantation. At the time of publication, nearly 2 years have passed since the transplantation, but both donors and recipients are doing well. In the future, it seems more likely that the number of elderly living donor kidney transplantation will rise. On one hand, there is no absolute contraindication for elderly donors, while on the other hand, the criteria for a living kidney donor must be strictly examined. Furthermore, careful observation of both donors and recipients after transplantation is required.


Subject(s)
Kidney Transplantation/methods , Living Donors , Adult , Age Factors , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Retrospective Studies
3.
Oncogene ; 36(20): 2791-2801, 2017 05 18.
Article in English | MEDLINE | ID: mdl-27893710

ABSTRACT

B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) is a component of the polycomb repressive complex 1 (PRC1) complex that is overexpressed in breast and other cancers, and promotes self-renewal of cancer stem-like cells. The oncogenic mucin 1 (MUC1) C-terminal (MUC1-C) subunit is similarly overexpressed in human carcinoma cells and has been linked to their self-renewal. There is no known relationship between MUC1-C and BMI1 in cancer. The present studies demonstrate that MUC1-C drives BMI1 transcription by a MYC-dependent mechanism in breast and other cancer cells. In addition, we show that MUC1-C blocks miR-200c-mediated downregulation of BMI1 expression. The functional significance of this MUC1-C→︀BMI1 pathway is supported by the demonstration that targeting MUC1-C suppresses BMI1-induced ubiquitylation of H2A and thereby derepresses homeobox HOXC5 and HOXC13 gene expression. Notably, our results further show that MUC1-C binds directly to BMI1 and promotes occupancy of BMI1 on the CDKN2A promoter. In concert with BMI1-induced repression of the p16INK4a tumor suppressor, we found that targeting MUC1-C is associated with induction of p16INK4a expression. In support of these results, analysis of three gene expresssion data sets demonstrated highly significant correlations between MUC1-C and BMI1 in breast cancers. These findings uncover a previously unrecognized role for MUC1-C in driving BMI1 expression and in directly interacting with this stem cell factor, linking MUC1-C with function of the PRC1 in epigenetic gene silencing.


Subject(s)
Mucin-1/metabolism , Neoplasms/metabolism , Polycomb Repressive Complex 1/metabolism , Amino Acid Motifs , Amino Acid Sequence , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p16/genetics , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Gene Expression Regulation, Neoplastic , Gene Silencing , Histones/metabolism , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Humans , Mucin-1/chemistry , Mucin-1/genetics , NF-kappa B/metabolism , Neoplasms/genetics , Promoter Regions, Genetic , Protein Binding , Protein Interaction Domains and Motifs , Proto-Oncogene Proteins c-myc/metabolism , Transcription, Genetic , Ubiquitination
4.
Clin Exp Immunol ; 159(2): 176-84, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19919568

ABSTRACT

Studies have demonstrated that B cells play important roles in systemic sclerosis (SSc), especially through the CD19/CD22 autoimmune loop. CD22 is a B cell-specific inhibitory receptor that dampens B cell antigen receptor (BCR) signalling via tyrosine phosphorylation-dependent mechanism. In this study, we examined the presence and functional property of circulating autoantibodies reacting with CD22 in systemic sclerosis. Serum samples from 10 tight skin (TSK/+) mice and 50 SSc patients were assessed for anti-CD22 autoantibodies by enzyme-linked immunosorbent assays using recombinant mouse or human CD22. The association between anti-CD22 antibodies and clinical features was also investigated in SSc patients. Furthermore, the influence of SSc serum including anti-CD22 autoantibodies for CD22 tyrosine phosphorylation was examined by Western blotting using phosphotyrosine-specific antibodies reacting with four major tyrosine motifs of CD22 cytoplasmic domain. Anti-CD22 autoantibodies were positive in 80% of TSK/+ mice and in 22% of SSc patients. Patients positive for anti-CD22 antibodies showed significantly higher modified Rodnan skin thickness score compared with patients negative for anti-CD22 antibodies. Furthermore, anti-CD22 antibodies from patients' sera were capable of reducing phosphorylation of all four CD22 tyrosine motifs, while sera negative for anti-CD22 antibodies did not affect CD22 phosphorylation. Thus, a subset of SSc patients possessed autoantibodies reacting with a major inhibitory B cell response regulator, CD22. Because these antibodies can interfere CD22-mediated suppression onto B cell activation in vitro, SSc B cells produce functional autoantibodies that can enhance their own activation. This unique regulation may contribute to the autoimmune aspect of SSc.


Subject(s)
Autoantibodies/immunology , B-Lymphocytes/immunology , Scleroderma, Systemic/immunology , Sialic Acid Binding Ig-like Lectin 2/immunology , Adult , Animals , Autoantibodies/blood , B-Lymphocytes/cytology , B-Lymphocytes/metabolism , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Phosphorylation , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/metabolism , Scleroderma, Systemic/blood , Scleroderma, Systemic/pathology , Sialic Acid Binding Ig-like Lectin 2/genetics , Sialic Acid Binding Ig-like Lectin 2/metabolism , Tyrosine/metabolism
5.
Clin Exp Rheumatol ; 27(5): 751-7, 2009.
Article in English | MEDLINE | ID: mdl-19917156

ABSTRACT

OBJECTIVES: To determine the prevalence and clinical correlation of autoantibody to activating transcription factor (ATF)-2, a transcription factor of ATF/CREB family, in patients with systemic sclerosis (SSc). METHODS: Anti-ATF-2 Ab was examined by ELISA and immunoblotting using human recombinant ATF-2. ATF-2 activity to bind target DNA was evaluated by ELISA using a plate coated with oligonucleotide containing the consensus binding site for ATF-2. RESULTS: IgG anti-ATF-2 Ab levels in SSc patients (n=69) were significantly higher than those in normal controls (n=26). SSc patients positive for IgG anti-ATF-2 Ab had significantly longer disease duration, more frequent presence of decreased %VC and %DLco, and elevated levels of serum IgG, serum IgA, and erythrocyte sedimentation rates than those negative. More-over, IgG anti-ATF-2 Ab levels correlated inversely with %VC or %DLco. The presence of anti-ATF-2 Ab in SSc patients was confirmed by immunoblotting analysis. IgG isolated from serum samples of SSc patients positive for IgG anti-ATF-2 Ab by ELISA slightly but significantly inhibited ATF-2 activity compared with normal controls. CONCLUSIONS: These results suggest that anti-ATF-2 Ab is a new autoantibody in SSc and that it serves as a novel serological marker for inflammation and lung involvement in SSc.


Subject(s)
Activating Transcription Factor 2/immunology , Autoantibodies/analysis , Fibrosis/immunology , Lung Diseases/immunology , Scleroderma, Systemic/immunology , Adult , Aged , Case-Control Studies , Female , Humans , Immunoglobulin G/analysis , Lung Diseases/pathology , Male , Middle Aged
6.
Clin Exp Immunol ; 153(2): 245-57, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18505425

ABSTRACT

The deposition of immune complexes (IC) induces an acute inflammatory response with tissue injury, for which the involvement of nitric oxide (NO) and carbon monoxide (CO) has been suggested. NO is induced by NO synthase (NOS) and CO is generated by haeme oxygenase (HO). Among HO isoenzymes, HO-1 is an induced type. To assess the role of NO and CO in the pathogenic process, the cutaneous reverse passive Arthus reaction was examined using NOS inhibitor, HO-1 stimulator and HO-1 inhibitor. To evaluate the reaction we considered oedema, tumour necrosis factor-alpha, interleukin-6, and neutrophil number. The values of these four parameters were significantly reduced in mice treated with HO-1 stimulator as compared with the positive control mice. Quite the reverse was observed in mice treated with HO-1 inhibitor. These results suggest that the HO-1/CO signalling pathway is a therapeutic target for human IC-mediated disease.


Subject(s)
Arthus Reaction/metabolism , Carbon Monoxide/metabolism , Cryoprotective Agents/metabolism , Skin/immunology , Animals , Arthus Reaction/immunology , Biomarkers/analysis , Female , Gases , Heme Oxygenase-1/analysis , Heme Oxygenase-1/antagonists & inhibitors , Heme Oxygenase-1/metabolism , Hemin/pharmacology , Immunohistochemistry , Interleukin-6/analysis , Mice , Mice, Inbred C57BL , Models, Animal , NG-Nitroarginine Methyl Ester/pharmacology , Neutrophils/immunology , Nitric Oxide/metabolism , Nitric Oxide Synthase/antagonists & inhibitors , Nitrites/analysis , Protoporphyrins/pharmacology , Spectrophotometry , Tumor Necrosis Factor-alpha/analysis
7.
Radiat Environ Biophys ; 47(3): 313-22, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18389270

ABSTRACT

In the process of developing a new dosimetry system for atomic bomb survivors in Hiroshima and Nagasaki (DS02), an intercomparison study between (152)Eu and (36)Cl measurements was proposed, to reconcile the discrepancy previously observed in the Hiroshima data between measurements and calculations of thermal neutron activation products. Nine granite samples, exposed to the atomic-bomb radiation in Hiroshima within 1,200 m of the hypocenter, as well as mixed standard solutions containing known amounts of europium and chlorine that were neutron-activated by a (252)Cf source, were used for the intercomparison. Gamma-ray spectrometry for (152)Eu was carried out with ultra low-background Ge detectors at the Ogoya Underground Laboratory, Kanazawa University, while three laboratories participated in the (36)Cl measurement using accelerator mass spectrometry (AMS): The Technical University of Munich, Germany, the Lawrence Livermore National Laboratory, USA and the University of Tsukuba, Japan. Measured values for the mixed standard solutions showed good agreement among the participant laboratories. They also agreed well with activation calculations, using the neutron fluences monitored during the (252)Cf irradiation, and the corresponding activation cross-sections taken from the JENDL-3.3 library. The measured-to-calculated ratios obtained were 1.02 for (152)Eu and 0.91-1.02 for (36)Cl, respectively. Similarly, the results of the granite intercomparison indicated good agreement with the DS02 calculation for these samples. An average measured-to-calculated ratio of 0.98 was obtained for all granite intercomparison measurements. The so-called neutron discrepancy that was previously observed and that which included increasing measured-to-calculated ratios for thermal neutron activation products for increasing distances beyond 1,000 m from the hypocenter was not seen in the results of the intercomparison study. The previously claimed discrepancy could be explained by insufficient understanding of the measured data.


Subject(s)
Chlorine , Europium , Gamma Rays , Nuclear Warfare , Radiometry , Humans , Japan , Mass Spectrometry
8.
Clin Exp Dermatol ; 33(3): 329-32, 2008 May.
Article in English | MEDLINE | ID: mdl-18312458

ABSTRACT

It is unclear whether any clinical and laboratory features are associated with pulmonary fibrosis (PF) in systemic sclerosis (SSc). We assessed these features using a database of 29 patients with SSc and anti-topoisomerase I antibodies and 68 patients with SSc and anticentromere antibody (ACA). Clinical features were not associated with the incidence of PF in patients with SSc and anti-topoisomerase I antibodies, although severe skin sclerosis was correlated with the presence of PF in patients with ACA. Serum IgG levels were often raised in patients with SSc and PF. Serum IgG levels in patients with PF were significantly higher than those in patients without PF, and were negatively correlated with percentage vital capacity and percentage diffusing capacity of the lung for carbon monoxide. In addition, serum IgG levels were correlated with serum interleukin-6. Thus, serum IgG levels are associated with PF in patients with SSc and anti-topoisomerase I antibodies and in patients with SSc and ACA.


Subject(s)
Centromere/immunology , DNA Topoisomerases, Type I/immunology , Immunoglobulin G/blood , Pulmonary Fibrosis/diagnosis , Scleroderma, Systemic/diagnosis , Adolescent , Adult , Aged , Biomarkers/blood , Child , Child, Preschool , Disease Susceptibility , Female , Humans , Interleukin-6/blood , Male , Middle Aged , Pulmonary Fibrosis/immunology , Scleroderma, Systemic/immunology
9.
Br J Dermatol ; 158(3): 487-95, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18205876

ABSTRACT

BACKGROUND: Systemic sclerosis (SSc) is a connective tissue disorder with excessive fibrosis of the skin and various internal organs. Although SSc is a heterogeneous disease, it has been reported that the particular antinuclear antibodies (ANA) are often indicative of clinical features, disease course and overall severity. OBJECTIVE: To clarify the association of clinical and prognostic features with serum ANA in Japanese patients with SSc. METHODS: We studied 203 Japanese patients diagnosed with SSc, who visited our hospital during the period 1983-2005. Six SSc-related ANA were identified using indirect immunofluorescence, double immunodiffusion and immunoprecipitation assays. RESULTS: Patients with SSc were classified into six ANA-based subgroups and a group without ANA. As expected, antitopoisomerase I antibody (Ab, n=64), anti-RNA polymerases (RNAP) Ab (n=12) and anti-U3 RNP Ab (n=5) were associated with diffuse cutaneous SSc, whereas anticentromere Ab (ACA, n=75), anti-Th/To Ab (n=7) and anti-U1 RNP Ab (n=10) were frequently detected in patients with limited cutaneous SSc. Clinical features of the ANA-negative group (n=10) were heterogeneous. Consistent with previous findings in Caucasian and/or black African patients, antitopoisomerase I Ab was associated with the involvement of vascular and pulmonary fibrosis, leading to decreased survival rate. However, no patients with anti-RNAP Ab developed renal crisis and the frequency of isolated pulmonary hypertension in patients with ACA, anti-Th/To Ab or anti-U3 RNP Ab was similar to that in other ANA-based subgroups. CONCLUSION: These results indicate that the clinical relevance of SSc-related ANA in Japanese patients differs in some aspects from that in Caucasian and/or black African patients.


Subject(s)
Antibodies, Antinuclear/genetics , DNA Topoisomerases, Type I/genetics , Scleroderma, Systemic/immunology , Antibodies, Antinuclear/analysis , Antibodies, Antinuclear/immunology , Asian People/ethnology , Cause of Death , DNA Topoisomerases, Type I/analysis , Female , Fibrosis , Humans , Japan/ethnology , Male , Middle Aged , Scleroderma, Systemic/drug therapy , Survival Rate
10.
Clin Exp Rheumatol ; 26(6): 998-1004, 2008.
Article in English | MEDLINE | ID: mdl-19210862

ABSTRACT

BACKGROUND: Systemic sclerosis (SSc) is characterized by autoantibodies against various cellular components. OBJECTIVE: To determine the presence or levels of antibodies (Abs) against a protease domain (PD) of caspase-8 and their clinical relevance in SSc. METHODS: Anti-caspase-8 PD Ab was examined by enzyme-linked immunosorbent assay and immunoblotting using human recombinant caspase-8 PD. Caspase-8 activity was evaluated by spectrophotometric detection of cleavage from p-nitroanilide-labeled IETD, a substrate of caspase-8. RESULTS: IgG anti-caspase-8 PD Ab levels in patients with SSc, systemic lupus erythematosus, or dermatomyositis were higher than in normal controls (CTL). Furthermore, anit-caspase-8 PD Ab levels in limited cutaneous SSc (ISSc) patients were elevated compared to diffuse cutameous SSc (dSSc) patients. To investigate the clinical correlation, laboratory findings were compared between SSc patients with high levels (>the mean+2SD of CTL) of anti-caspase-8 PD Ab and those with low levels. SSc patients with high level exhibited lower frequency of male and decreased C-reactive protein levels relative to those with low levels. Immunoblotting showed the anit-caspase-8 PD Ab was present in all SSc patients examined, while it was also detected in 75% of CTL. Caspase-8 activity was inhibited by IgG isolated from sera of SSc patients and CTL, although inhibitory effect was greater in SSc patients than CTL. CONCLUSION: These results suggest that immune response to caspase-8 occurs in healthy individuals, although it is greater in patients with systemic autoimmune diseases including SSc. Furthermore, high level of anti-caspase-8 PD Ab may be a serological indicator for a milder SSc subset.


Subject(s)
Autoantibodies/blood , Autoimmunity , Caspase 8/immunology , Scleroderma, Systemic/immunology , Adult , Aged , Caspase 8/chemistry , Caspase 8/metabolism , Enzyme Activation/immunology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Middle Aged , Protein Structure, Tertiary , Scleroderma, Systemic/metabolism , Severity of Illness Index
11.
Ann Oncol ; 19(1): 49-55, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17965113

ABSTRACT

BACKGROUND: This study explored the psychological and behavioral mechanisms of complementary and alternative medicine (CAM) use in Japanese cancer patients using two applied behavioral models, the transtheoretical model (TTM), and theory of planned behavior (TPB). PATIENTS AND METHODS: Questionnaires were distributed to 1100 patients at three cancer treatment facilities in Japan and data on 521 cancer patients were used in the final analysis. The questionnaire included items based on TTM and TPB variables, as well as three psychological batteries. RESULTS: According to the TTM, 88 patients (17%) were in precontemplation, 226 (43%) in contemplation, 33 (6%) in preparation, 71 (14%) in action, and 103 (20%) in maintenance. The model derived from structural equation modeling revealed that the stage of CAM use was significantly affected by the pros, cons, expectation from family, norms of medical staff, use of chemotherapy, period from diagnosis, and place of treatment. The primary factor for the stage of CAM use was the expectation from family. CONCLUSIONS: The findings revealed the existence of a number of psychologically induced potential CAM users, and psychological variables including positive attitude for CAM use and perceived family expectation greatly influence CAM use in cancer patients.


Subject(s)
Complementary Therapies/psychology , Neoplasms/psychology , Patient Acceptance of Health Care/psychology , Adult , Aged , Attitude to Health , Combined Modality Therapy/psychology , Complementary Therapies/statistics & numerical data , Cross-Sectional Studies , Family Relations , Female , Humans , Japan , Male , Middle Aged , Models, Psychological , Neoplasms/therapy , Professional-Patient Relations , Psychological Tests , Surveys and Questionnaires
12.
Ann Rheum Dis ; 67(6): 867-72, 2008 Jun.
Article in English | MEDLINE | ID: mdl-17823201

ABSTRACT

OBJECTIVE: To assess the association of CD40/CD40 ligand (CD40L) interactions with the development of skin fibrosis and autoimmunity in tight-skin (TSK/+) mouse, which is a mouse model for human systemic sclerosis. METHODS: Newly born TSK/+ mice were treated with murine anti-CD40L monoclonal antibody (100 microg intraperitoneally weekly). Hypodermal thickness of 8-week-old female mice (defined as the thickness of a subcutaneous loose connective tissue layer beneath the panniculus carnosus) was measured under a light microscope. All skin sections were taken from the para-midline, upper back region. Serum anti-topoisomerase I autoantibody levels, serum immunoglobulin levels and plasma soluble CD40L levels were determined by enzyme-linked immunosorbent assay. For analysis of lymphocyte surface molecules, single cell suspensions of lymphocytes were stained by monoclonal antibodies. Proliferation of TSK/+ B cells and fibroblasts to anti-CD40 antibodies was assessed by the uptake of [3H]-labelled thymidine and bromodeoxyuridine, respectively. RESULTS: The blockade of CD40/CD40L interactions by anti-CD40L monoclonal antibody significantly reduced cutaneous fibrosis (65%) and anti-topoisomerase I autoantibody in TSK/+ mice. Anti-CD40L monoclonal antibody also normalised B lymphocyte abnormal activation in TSK/+ mice, demonstrated by hyper-gamma-globulinaemia. Furthermore, augmented CD40/CD40L interactions in TSK/+ mice were suggested by upregulated expression of CD40L on CD4(+) T cells, elevated plasma soluble CD40L levels. The hyperresponsiveness to CD40 stimulation was also observed in TSK/+ B cells and fibroblasts. CONCLUSIONS: Cutaneous fibrosis and autoimmunity in TSK/+ mice are closely correlated with CD40/CD40L interactions.


Subject(s)
Antibodies, Blocking/therapeutic use , Antibodies, Monoclonal/therapeutic use , CD40 Ligand/immunology , Scleroderma, Systemic/therapy , Animals , Autoantibodies/blood , Autoimmunity , B-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/immunology , CD40 Ligand/antagonists & inhibitors , CD40 Ligand/blood , Cell Proliferation , DNA Topoisomerases, Type I/immunology , Disease Models, Animal , Female , Fibrosis , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Scleroderma, Systemic/immunology , Scleroderma, Systemic/pathology , Skin/pathology , Up-Regulation
13.
Clin Exp Rheumatol ; 25(2): 281-6, 2007.
Article in English | MEDLINE | ID: mdl-17543154

ABSTRACT

OBJECTIVE: To determine serum levels of nitrotyrosine (NT), an end product of peroxynitrite (ONOO-), and its clinical association in patients with systemic sclerosis (SSc). METHODS: Serum NT levels from 25 patients with limited cutaneous SSc (lSSc) and 34 patients with diffuse cutaneous SSc (dSSc) were examined by enzyme-linked immunosorbent assay. RESULTS: Serum NT levels were elevated in SSc patients compared with normal controls (n = 27), the levels being similar between lSSc and dSSc patients (P < 0.001). SSc patients with elevated NT had higher serum levels of anti- agalactosyl IgG Ab, IgG and IgA than those with normal NT levels (P < 0.05). NT levels correlated inversely with the percentage diffusion capacity for carbon monoxide (DLco) (P < 0.02, r = -0.414, n = 47). CONCLUSION: These results suggest that ONOO- may play an important role in the clinical manifestations of SSc, especially vascular damage to the lungs, and that ONOO- may be related to immunological abnormalities in SSc.


Subject(s)
Peroxynitrous Acid/metabolism , Scleroderma, Systemic/metabolism , Tyrosine/analogs & derivatives , Adult , Biomarkers/blood , Carbon Monoxide/metabolism , Case-Control Studies , Female , Gene Expression Regulation , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Lung/blood supply , Lung/pathology , Male , Middle Aged , Peroxynitrous Acid/genetics , Scleroderma, Systemic/blood , Tyrosine/blood
14.
Sci Total Environ ; 381(1-3): 243-55, 2007 Aug 01.
Article in English | MEDLINE | ID: mdl-17459459

ABSTRACT

The present plutonium and 137Cs concentrations in South Pacific Ocean surface waters were determined. The water samples were collected in the South Pacific mid-latitude region (32.5 degrees S) during the BEAGLE expedition conducted in 2003-04 by JAMSTEC. 239,240Pu concentrations in surface seawater of the South Pacific were in the range of 0.5 to 4.1 mBq m(-3), whereas 137Cs concentrations ranged from 0.07 to 1.7 Bq m(-3). The observed 239,240Pu and 137Cs concentrations in the South Pacific were almost of the same level as those in the North Pacific subtropical gyre. The surface 239,240Pu in the South Pacific subtropical gyre showed larger spatial variations than 137Cs, as it may be affected by physical and biogeochemical processes. The 239,240Pu/137Cs activity ratios, which reflect biogeochemical processes in seawater, were generally smaller than that observed in global fallout, except for the most eastern station. The 239,240Pu/137Cs ratios in the South Pacific tend to be higher than that in the North Pacific. The relationships between anthropogenic radionuclides and oceanographic parameters such as salinity and nutrients were examined. The 137Cs concentrations in the western South Pacific (the Tasman Sea) and the eastern South Pacific were negatively correlated with the phosphate concentration, whereas there is no correlation between the 137Cs and nutrients concentrations in the South Pacific subtropical gyre. The mutual relationships between anthropogenic radionuclides and oceanographic parameters are important for better understanding of transport processes of anthropogenic radionuclides and their fate in the South Pacific.


Subject(s)
Cesium Radioisotopes/analysis , Plutonium/analysis , Radiation Monitoring , Seawater/chemistry , Water Pollutants, Radioactive/analysis , Pacific Ocean , Sodium Chloride/analysis , Water Movements
15.
J Environ Radioact ; 96(1-3): 103-9, 2007.
Article in English | MEDLINE | ID: mdl-17428591

ABSTRACT

Cosmic-ray-produced (CP) nuclides with half-lives shorter than 21h were measured in rainwater by ultra-low-background gamma spectrometry at Ogoya Underground Laboratory. As levels of CP nuclides are extremely low and their half-lives are very short, quick sampling methods for a large volume of rainwater and rapid chemical separations by ion exchange method were developed. The nuclides measured were short-lived (24)Na, (28)Mg, (38)S, (38)Cl, (39)Cl, as well as nuclides with longer half-lives (7)Be and (22)Na. The number of atoms of CP nuclides in rainwater were evaluated to range from 30 to 1500L(-1) for (24)Na (n=16, mean; 520 [6.7mBqL(-1)]), 80 to 600L(-1) for (28)Mg (n=13, mean; 260 [2.4mBqL(-1)]), 400 to 1900L(-1) for (39)Cl (n=6, mean; 1200 [250mBqL(-1)]), 1x10(6) to 4x10(7)L(-1) for (7)Be (n=16, mean; 7x10(6) [1.05BqL(-1)]) and 2x10(3) to 1x10(5)L(-1) for (22)Na (n=9, mean; 2x10(4) [0.2mBqL(-1)]).


Subject(s)
Cosmic Radiation , Environmental Monitoring/methods , Radioisotopes/analysis , Water Pollutants, Radioactive/analysis , Beryllium/analysis , Chlorine/analysis , Magnesium/analysis , Radiation Monitoring , Rain , Seasons , Sodium Radioisotopes/analysis , Spectrometry, Gamma/methods , Sulfur Radioisotopes/analysis , Time Factors
16.
Health Phys ; 92(4): 366-77, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17351501

ABSTRACT

In order to resolve the discrepancy between the measured and calculated 152Eu activity induced by the atomic bomb at Hiroshima, extremely low background gamma-ray spectrometry was performed for 17 granite samples collected from 134 m to more than 3 km from the hypocenter. Measurements agreed well with theoretical calculations based on DS02 up to 1.4 km from hypocenter.


Subject(s)
Algorithms , Europium/analysis , Explosive Agents/adverse effects , Fast Neutrons/adverse effects , Nuclear Warfare , Silicon Dioxide/analysis , Japan , Radiation Dosage , Spectrometry, Gamma/methods
17.
Rheumatology (Oxford) ; 46(5): 790-5, 2007 May.
Article in English | MEDLINE | ID: mdl-17309887

ABSTRACT

OBJECTIVES: To determine the prevalence and clinical correlation of autoantibody to peroxiredoxin (Prx) I, an antioxidant enzyme, in patients with systemic sclerosis (SSc). METHODS: Serum samples from SSc patients (n = 70) and healthy controls (n = 23) were examined by ELISA using human recombinant Prx I. The presence of anti-Prx I antibody was further evaluated by immunoblotting analysis. To determine the functional relevance of anti-Prx I antibody in vivo, we assessed whether anti-Prx I antibody was able to inhibit Prx I enzymatic activity using yeast thioredoxin reductase system. RESULTS: IgG anti-Prx I antibody levels in SSc patients were significantly higher than healthy controls and this autoantibody was detected in 33% of SSc patients. The presence of IgG anti-Prx I antibody was associated with longer disease duration, more frequent presence of pulmonary fibrosis, heart involvement, and anti-topoisomerase I antibody and increased levels of serum immunoglobulin and erythrocyte sedimentation rates. IgG anti-Prx I antibody levels also correlated positively with renal vascular damage and negatively with pulmonary function tests. Furthermore, anti-Prx I antibody levels correlated positively with serum levels of 8-isoprostane, a marker of oxidative stress. Immunoblotting analysis confirmed the presence of anti-Prx I antibody. Remarkably, Prx I enzymatic activity was inhibited by IgG isolated from SSc sera containing IgG anti-Prx I antibody. CONCLUSIONS: These results suggest that elevated IgG anti-Prx I autoantibody is associated with the disease severity of SSc and that anti-PrxI antibody may enhance the oxidative stress by inhibiting Prx I enzymatic activity.


Subject(s)
Antioxidants/physiology , Autoantibodies/blood , Oxidative Stress/immunology , Peroxidases/immunology , Scleroderma, Systemic/immunology , Adult , Aged , Dinoprost/analogs & derivatives , Dinoprost/blood , Enzyme Inhibitors/pharmacology , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Immunoglobulin G/blood , Immunoglobulin G/pharmacology , Male , Middle Aged , Peroxidases/antagonists & inhibitors , Peroxiredoxins , Pulsatile Flow , Severity of Illness Index , Vital Capacity
18.
Rheumatology (Oxford) ; 46(1): 25-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16728436

ABSTRACT

OBJECTIVE: Myositis-specific autoantibodies (MSAs) are a useful tool in diagnosis, defining clinical subsets and predicting prognosis of dermatomyositis (DM) and polymyositis (PM). In this study, we identified a novel MSA reactive with 155 and 140 kDa nuclear proteins [anti-155/140 antibody (Ab)] and determined the clinical feature of DM patients positive for this autoantibody (autoAb). METHODS: Sera from 52 Japanese patients with DM, 9 with PM, 48 with systemic lupus erythematosus (SLE), 126 with systemic sclerosis and 18 with idiopathic interstitial pneumonia were examined by immunoprecipitation assays. Positive sera were further characterized by immunodepletion and immunofluorescence staining. RESULTS: Seven of the 52 (13%) Japanese patients with DM immunoprecipitated 155 and 140 kDa proteins from 35S-labelled K562 leukaemia cell extract. No patients with SLE, systemic sclerosis or idiopathic interstitial pneumonia as well as healthy controls were positive for this autoAb. Patients with anti-155/140 Ab developed heliotrope rash, Gottron's papules or sign and flagellate erythema significantly more frequently than those negative. Notably, internal malignancy was found at significantly higher frequency in those positive than those negative (71 vs 11%; P < 0.005). In contrast, none of these patients positive for this autoAb had interstitial lung disease. CONCLUSIONS: This novel MSA is associated with cancer-associated DM and may serve as a diagnostic serological marker for this specific subset.


Subject(s)
Antibodies, Antinuclear/blood , Dermatomyositis/diagnosis , Neoplasms/complications , Nuclear Proteins/immunology , Paraneoplastic Syndromes/diagnosis , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Dermatomyositis/etiology , Dermatomyositis/immunology , Electrophoresis, Polyacrylamide Gel/methods , Female , Humans , Immunoprecipitation/methods , K562 Cells , Lung Diseases, Interstitial/immunology , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Neoplasms/immunology , Paraneoplastic Syndromes/etiology , Paraneoplastic Syndromes/immunology , Scleroderma, Systemic/immunology
19.
Dermatology ; 213(2): 88-92, 2006.
Article in English | MEDLINE | ID: mdl-16902284

ABSTRACT

BACKGROUND: The transforming growth factor-beta (TGF-beta) system plays a critical role both in systemic sclerosis (SSc) and hereditary hemorrhagic telangiectasia (HHT). Endoglin, known as a gene responsible for HHT, is a TGF-beta receptor preferentially expressed on endothelial cells. The role of endoglin in SSc is potentially intriguing since limited cutaneous SSc (lcSSc) and HHT share several symptoms, including telangiectasia. OBJECTIVE: To determine serum levels of soluble endoglin (sEndoglin) and clinical associations in patients with SSc. METHODS: Serum sEndoglin levels were examined by ELISA in 70 patients with SSc, 20 patients with systemic lupus erythematosus and 20 healthy individuals. RESULTS: Serum sEndoglin levels were significantly elevated in patients with lcSSc compared with diffuse cutaneous SSc and systemic lupus erythematosus patients as well as normal controls. Patients with elevated sEndoglin levels had telangiectasia more frequently than those with normal sEndoglin levels. Furthermore, pulmonary artery pressure was positively correlated with sEndoglin levels in patients with lcSSc. CONCLUSION: Abnormal expression/function of endoglin may be linked to lcSSc-specific manifestations.


Subject(s)
Antigens, CD/blood , Receptors, Cell Surface/blood , Scleroderma, Systemic/blood , Telangiectasia, Hereditary Hemorrhagic/blood , Adolescent , Adult , Aged , Biomarkers/blood , Child , Endoglin , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Humans , Male , Middle Aged , Scleroderma, Systemic/complications , Severity of Illness Index , Telangiectasia, Hereditary Hemorrhagic/complications
20.
J Environ Radioact ; 89(2): 138-49, 2006.
Article in English | MEDLINE | ID: mdl-16762463

ABSTRACT

In this study, low-background gamma-spectrometry was used to determine the (228)Ra/(226)Ra ratio of 131 coastal water samples from various environments around Honshu Island, Japan (mainly around Noto Peninsula) at 1-3 month intervals from April 2003 until September 2005. Spatial variation in (228)Ra/(226)Ra ratios was also assessed by analyzing 34 coastal water samples from five areas within the Sea of Japan during May and June 2004. The (228)Ra/(226)Ra ratio of coastal water from all sites around Noto Peninsula shows seasonal variation, with minimum values during summer ((228)Ra/(226)Ra=0.7) and maximum values during autumn-winter ((228)Ra/(226)Ra=1.7-2). This seasonal variation is similar to that recorded for coastal water between Tsushima Strait and Noto Peninsula. The measured lateral variation in (228)Ra/(226)Ra ratios within coastal water between Tsushima Strait and Noto Peninsula is only minor (0.5-0.7; May-June 2004). Coastal waters from two other sites (Pacific shore and Tsugaru Strait, north Honshu) show no clear seasonal variation in (228)Ra/(226)Ra ratio. These measured variations in (228)Ra/(226)Ra ratio, especially the temporal variations, have important implications for seasonal changes in patterns of coastal water circulation within the Sea of Japan.


Subject(s)
Radium/metabolism , Seasons , Seawater/chemistry , Water Movements , Environmental Monitoring , Humans , Japan , Oceans and Seas , Radioisotopes/metabolism , Radium/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...